September 10, 2025OncoImmunologyOpen Access

Immune modulation following α and β − radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis reveals immune activation and responses in C57BL/6 mice post-radionuclide therapy, indicating therapeutic potential.

The therapy activated a variety of immune responses in tumors and the periphery, enhancing immune activity.
PD-1 expression on CD8+ T-cells increased following treatments with both radionuclides, suggesting T-cell involvement.
Flow cytometry and RNA sequencing were utilized to characterize systemic immune responses and tumor characteristics.
Findings highlight the potential of radionuclide therapy to sensitize immune responses, suggesting avenues for cancer treatment.

Ceuppens et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark